The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
Transplant patients are at particular risk for developing post-transplant lymphoproliferative disease (PTLD) following administration of immunosuppressive therapy. In many cases the PTLD lesions express Epstein-Barr virus (EBV) latent and lytic genes as well as elevated levels of host cytokines. An outline of the potential contributions of EBV, host cytokines and T cells, and the immunosuppressive cyclosporine A, tacrolimus, and anti-CD3 antibody in the mechanism and pathogenesis of this disease is presented and discussed.
Tanner
J E
JE
Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa Medical School, Ottawa, Ontario, Canada.
Alfieri
C
C
D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000472:pathogenicity*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications